COVID-19 vaccine elicits weak antibody response in people taking immunosuppressant

Posted by Michael Jannicelli | Nov 19, 2021 | Uncategorized | 0 |

People taking TNF inhibitors, a kind of immunosuppressive drug used to treat rheumatoid arthritis and other autoimmune conditions, produced a weaker and shorter-lived antibody response after two doses of Pfizer’s COVID-19 vaccine, according to a new study. A third vaccine dose drove antibody levels back up, indicating that this additional dose may provide protection as the virus’s delta variant continues to spread.

About The Author

Michael Jannicelli

Michael Jannicelli - "A PROVEN BUSINESS FIRESTARTER & BRANDING GENIUS" a true natural born Trendsetter. • Created over 100 products under 3 brands, sold in 30+ countries worldwide and influencing youth across the globe. • Featured in Forbes magazine +over 100 print publications, television talk shows, major motion pictures and national radio stations. • Co-founder and VP of Bliss beverage USA and President/co-founder of Socko International - fastest growing privately held beverage company in US (Forbes) with Hogan Energy & Raw Energy WWE. • Co-founder of Throwdown Industries (2003) - leading brand in multibillion dollar Impact/Action Sports Market (products designed for superior MN • Diagnosed with auto-immune diseases aged 13; using his experience to help others and promote a positive message while developing edgy products to benefit people with chronic illness.